Wall Street Analysts See a 75.05% Upside in HUTCHMED (HCM): Can the Stock Really Move This High?
https://www.zacks.com/stock/news/2227980/wall-street-analysts-see-a-75-05-upside-in-hutchmed-hcm-can-the-stock-really-move-this-high?cid=CS-ZC-FT-tale_of_the_tape|consensus_price_target-2227980
Feb 19, 2024 - The average of price targets set by Wall Street analysts indicates a potential upside of 75.1% in HUTCHMED (HCM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
0
Paycor HCM (PYCR) Q2 2024 Earnings Call Transcript
https://www.fool.com/earnings/call-transcripts/2024/02/07/paycor-hcm-pycr-q2-2024-earnings-call-transcript/?source=iedfolrf0000001
Feb 07, 2024 - PYCR earnings call for the period ending December 31, 2023.
0
Ceridian HCM (CDAY) Reports Next Week: Wall Street Expects Earnings Growth
https://www.zacks.com/stock/news/2218779/ceridian-hcm-cday-reports-next-week-wall-street-expects-earnings-growth?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2218779
Jan 31, 2024 - Ceridian (CDAY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
0
After Plunging -10.7% in 4 Weeks, Here's Why the Trend Might Reverse for HUTCHMED (HCM)
https://www.zacks.com/stock/news/2212072/after-plunging-10-7-in-4-weeks-here-s-why-the-trend-might-reverse-for-hutchmed-hcm?cid=CS-ZC-FT-tale_of_the_tape|rsi-2212072
Jan 18, 2024 - HUTCHMED (HCM) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
0
Cytokinetics Steps Up As Prime Target After Aficamten's HCM Triumph (Rating Upgrade)
https://seekingalpha.com/article/4662436-cytokinetics-steps-up-prime-target-aficamtens-hcm-triumph?source=feed_all_articles
Jan 11, 2024 - Cytokinetics is almost certainly fielding several bids from a few different companies. Click here to see why CYTK stock is a Buy.
0
Here's Why Ceridian HCM (CDAY) is a Must-Buy Stock in 2024
https://www.zacks.com/stock/news/2204586/here-s-why-ceridian-hcm-cday-is-a-must-buy-stock-in-2024?cid=CS-ZC-FT-analyst_blog|rank_focused-2204586
Jan 02, 2024 - Ceridian HCM (CDAY) is benefiting from an expanding clientele and a robust portfolio.
0
Needham says Cytokinetics' appeal as M&A target enhanced by HCM data
https://seekingalpha.com/news/4051040-needham-says-cytokinetics-appeal-as-ma-target-enhanced-by-hcm-data?source=feed_sector_healthcare
Dec 28, 2023 - Cytokinetics' (CYTK) attractiveness as a takeover target has been enhanced by positive data for its hypertrophic cardiomyopathy drug aficamten, according to Needham.
0
Pages: 1
Page 1